Sunmax Biotechnology Co Ltd Total Assets

Latest as of September 2025: NT$1.90 Billion TWD ≈ $59.82 Million USD

Sunmax Biotechnology Co Ltd total assets. Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) holds total assets worth NT$1.90 Billion TWD (≈ $59.82 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Sunmax Biotechnology Co Ltd market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Sunmax Biotechnology Co Ltd (2015–2024)

Total assets of Sunmax Biotechnology Co Ltd from 2015 to 2024. This chart illustrates how Sunmax Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. See Sunmax Biotechnology Co Ltd stock price for real-time trading data and today's change.

Sunmax Biotechnology Co Ltd - Asset Composition Analysis

Sunmax Biotechnology Co Ltd Total Assets Breakdown (December 2024)

Sunmax Biotechnology Co Ltd total assets breakdown as of December 2024. Sunmax Biotechnology Co Ltd's total assets of NT$1.90 Billion consist of 32.1% current assets and 67.9% non-current assets.

Asset Category Amount (TWD) % of Total Assets
Cash & Equivalents NT$0.00 13.1%
Accounts Receivable NT$100.22 Million 5.4%
Inventory NT$125.95 Million 6.8%
Property, Plant & Equipment NT$0.00 0.0%
Intangible Assets NT$5.75 Million 0.3%
Goodwill NT$0.00 0.0%

Asset Composition Trend (2015–2024)

This chart illustrates how Sunmax Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sunmax Biotechnology Co Ltd (4728) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Sunmax Biotechnology Co Ltd's current assets represent 32.1% of total assets in 2024, a decrease from 80.1% in 2015.
  • Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, down from 71.5% in 2015.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2015.
  • Asset Diversification: The largest asset category is inventory at 6.8% of total assets.

Sunmax Biotechnology Co Ltd Competitors by Total Assets

Key competitors of Sunmax Biotechnology Co Ltd based on total assets are shown below.

Company Country Total Assets
argenx NV ADR
NASDAQ:ARGX
USA $10.03 Billion
Argen-X
F:1AE
Germany €8.68 Billion
Ascendis Pharma AS
F:A71
Germany €2.00 Billion
Halozyme Therapeutics Inc
NASDAQ:HALO
USA $3.47 Billion
Abivax SA American Depositary Shares
NASDAQ:ABVX
USA $462.21 Million
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
USA $2.19 Billion
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
China CN¥13.56 Billion
SOLENO THERAPEUT. DL-001
F:6XC
Germany €563.83 Million

Sunmax Biotechnology Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.85 3.40 3.28
Quick Ratio 3.20 2.83 3.19
Cash Ratio 0.00 0.00 0.00
Working Capital NT$689.03 Million NT$600.84 Million NT$671.01 Million

Sunmax Biotechnology Co Ltd - Advanced Valuation Insights

This section examines the relationship between Sunmax Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 14.69
Latest Market Cap to Assets Ratio 0.37
Asset Growth Rate (YoY) -14.3%
Total Assets NT$1.85 Billion
Market Capitalization $680.35 Million USD

Valuation Analysis

Below Book Valuation: The market values Sunmax Biotechnology Co Ltd's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Sunmax Biotechnology Co Ltd's assets decreased by 14.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Sunmax Biotechnology Co Ltd (2015–2024)

The table below shows the annual total assets of Sunmax Biotechnology Co Ltd from 2015 to 2024.

Year Total Assets Change
2024-12-31 NT$1.85 Billion
≈ $58.31 Million
-14.28%
2023-12-31 NT$2.16 Billion
≈ $68.02 Million
+20.40%
2022-12-31 NT$1.79 Billion
≈ $56.50 Million
+20.84%
2021-12-31 NT$1.48 Billion
≈ $46.75 Million
+8.79%
2020-12-31 NT$1.36 Billion
≈ $42.98 Million
+22.60%
2019-12-31 NT$1.11 Billion
≈ $35.05 Million
+46.81%
2018-12-31 NT$757.89 Million
≈ $23.88 Million
+14.67%
2017-12-31 NT$660.92 Million
≈ $20.82 Million
+10.62%
2016-12-31 NT$597.49 Million
≈ $18.82 Million
-0.84%
2015-12-31 NT$602.57 Million
≈ $18.98 Million
--

About Sunmax Biotechnology Co Ltd

TWO:4728 Taiwan Biotechnology
Market Cap
$680.35 Million
NT$21.59 Billion TWD
Market Cap Rank
#10019 Global
#304 in Taiwan
Share Price
NT$396.50
Change (1 day)
+4.62%
52-Week Range
NT$373.00 - NT$409.00
All Time High
NT$494.50
About

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.